Trial Profile
Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Conjunctival disorders; Follicular lymphoma; Lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions
- Acronyms IRIS
- 02 Aug 2022 Status changed from recruiting to completed.
- 29 Sep 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2011-004908-37).
- 27 Jan 2012 New trial record